Related Experiment Videos

Hypolipemic agents for stroke prevention

Didier Leys1, Dominique Deplanque, Christian Lucas

  • 1dleys@chru-lille.fr

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|November 27, 2002
PubMed

Insights

Lowering cholesterol with hypolipidemic agents is crucial for stroke prevention. Studies show these agents reduce stroke incidence, particularly in high-risk patients, by addressing hypercholesterolemia.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Hypercholesterolemia is a significant risk factor for stroke.
  • Effective stroke prevention strategies require identifying and treating lipid disorders.

Purpose of the Study:

  • To evaluate the role of hypolipidemic agents in stroke prevention.
  • To consolidate evidence supporting lipid-lowering therapies for reducing stroke incidence.

Main Methods:

  • Review of randomized trials in coronary heart disease patients.
  • Analysis of pooled data from primary and secondary stroke prevention trials.
  • Examination of animal models for neuroprotective effects of hypolipidemic agents.

Main Results:

  • Established statistical link between abnormal lipid levels (high LDL-c, low HDL-c) and ischemic stroke.
  • Demonstrated reduction in vascular risk and plaque progression with lipid-lowering therapies.
  • Pooled analyses confirm cholesterol reduction decreases stroke incidence, especially in high-risk individuals.

Conclusions:

  • Hypolipidemic agents show promise for stroke prevention.
  • Further confirmation in stroke patients is warranted based on existing cardiovascular and asymptomatic individual trial data.
  • Lipid management is a key component of comprehensive stroke prevention.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...